PubMed COVID-19 Clinical Care

Immediate hypersensitivity reactions to vaccines, the most severe of which is anaphylaxis, are uncommon events occurring in less than 1 in a million doses administered. These reactions are infrequently IgE-mediated. Since they are unlikely to recur

CONCLUSION: Overall, more recent Ig products (expiration dates: 2023 - 2025) contained significantly higher binding and inhibition activities against SARS-CoV-2 proteins, as compared to earlier, or pre-pandemic products. Normal donor SARS-CoV-2

CONCLUSION: SARS-CoV-2 vaccines conferred low and transient protection against Omicron infection.

BACKGROUND: We aimed to identify trajectories of the evolution of post COVID-19 condition, up to two years after symptom onset.

CONCLUSION: No increased risk of environmental contamination in the isolation rooms was observed in the use of HFNC and NIV versus COT among COVID-19 patients with respiratory failure. Higher viral load in the respiratory samples was associated with

Long COVID-19 (LC-19) is a condition that has affected a high percentage of the population that recovered from the initial disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). LC-19 diagnosis is currently poorly defined

Despite the successes of current coronavirus disease 2019 (COVID-19) vaccines, waning immunity, the emergence of variants of concern, and breakthrough infections among vaccinees have begun to highlight opportunities to improve vaccine platforms. Real

Pneumonia is an acute inflammation of the lungs induced by pathogenic microorganisms, immune damage, physical and chemical factors, and other factors, and the latest outbreak of novel coronavirus pneumonia is also an acute lung injury (ALI) induced

CONCLUSION: The findings associated with recovery and convalescence define a new signature of cellular immune response that persists in individuals with SARS-CoV-2 infection and vaccination. The findings will help in providing a better understanding

No abstract